These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 14522632)

  • 1. Erythema multiforme-like eruption as a result of 'Solaraze' treatment.
    Young J
    J Dermatolog Treat; 2003 Sep; 14(3):189. PubMed ID: 14522632
    [No Abstract]   [Full Text] [Related]  

  • 2. 3% diclofenac in 2.5% hyaluronic acid (Solaraze) does not induce photosensitivity or phototoxicity alone or in combination with sunscreens.
    Ortonne JP; Queille-Roussel C; Duteil L
    Eur J Dermatol; 2006; 16(4):385-90. PubMed ID: 16935795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reassessment of topical diclofenac/hyaluronan gel for actinic keratoses.
    Burkhart CN; Burkhart CG
    Int J Dermatol; 2002 Jun; 41(6):371-2. PubMed ID: 12100697
    [No Abstract]   [Full Text] [Related]  

  • 4. Photoallergic contact dermatitis from topical diclofenac in Solaraze gel.
    Kowalzick L; Ziegler H
    Contact Dermatitis; 2006 Jun; 54(6):348-9. PubMed ID: 16787462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis.
    Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z
    J Dermatolog Treat; 2008; 19(3):159-63. PubMed ID: 18569272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses.
    Rivers JK; McLean DI
    Arch Dermatol; 1997 Oct; 133(10):1239-42. PubMed ID: 9382562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses.
    Rivers JK
    Skin Therapy Lett; 2004 Jan; 9(1):1-3. PubMed ID: 14716439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diclofenac/hyaluronic acid.
    Peters DC; Foster RH
    Drugs Aging; 1999 Apr; 14(4):313-9; discussion 320-1. PubMed ID: 10319244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of diclofenac for the management and treatment of actinic keratoses.
    Iraji F; Siadat AH; Asilian A; Enshaieh S; Shahmoradi Z
    Expert Opin Drug Saf; 2008 Mar; 7(2):167-72. PubMed ID: 18324879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-arm, open-label efficacy and tolerability study of diclofenac sodium 3% gel for the treatment of actinic keratosis of the upper and lower lip.
    Nelson CG; Spencer J; Nelson CG
    J Drugs Dermatol; 2007 Jul; 6(7):712-7. PubMed ID: 17763595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contact dermatitis from 3 different allergens in Solaraze gel.
    Kleyn CE; Bharati A; King CM
    Contact Dermatitis; 2004 Oct; 51(4):215-6. PubMed ID: 15500677
    [No Abstract]   [Full Text] [Related]  

  • 12. Topical treatment of actinic keratosis with 3.0% diclofenac in 2.5% hyaluronan gel: review of the literature about the cumulative evidence of its efficacy and safety.
    Javor S; Cozzani E; Parodi A
    G Ital Dermatol Venereol; 2016 Jun; 151(3):275-80. PubMed ID: 26512929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze).
    Nelson C; Rigel D; Smith S; Swanson N; Wolf J
    J Drugs Dermatol; 2004; 3(4):401-7. PubMed ID: 15303784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical 3% diclofenac in 2.5% hyaluronic acid gel: a review of its use in patients with actinic keratoses.
    Jarvis B; Figgitt DP
    Am J Clin Dermatol; 2003; 4(3):203-13. PubMed ID: 12627996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New and emerging topical approaches for actinic keratoses.
    Del Rosso JQ
    Cutis; 2003 Oct; 72(4):273-6, 279. PubMed ID: 14604078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical diclofenac: new preparation. Moderate efficacy in actinic keratosis.
    Prescrire Int; 2004 Aug; 13(72):138-9. PubMed ID: 15532138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does progression from actinic keratosis and Bowen's disease end with treatment: diclofenac 3% gel, an old drug in a new environment?
    Patel MJ; Stockfleth E
    Br J Dermatol; 2007 May; 156 Suppl 3():53-6. PubMed ID: 17488408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two cases of Bowen's disease successfully treated topically with 3% diclofenac in 2.5% hyaluronan gel.
    Dawe SA; Salisbury JR; Higgins E
    Clin Exp Dermatol; 2005 Nov; 30(6):712-3. PubMed ID: 16197397
    [No Abstract]   [Full Text] [Related]  

  • 19. Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses.
    Dirschka T; Bierhoff E; Pflugfelder A; Garbe C
    J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):258-63. PubMed ID: 19709346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New and emerging treatments for nonmelanomas and actinic keratoses.
    Peterson SR; Goldberg LH
    J Drugs Dermatol; 2003 Aug; 2(4):429-32. PubMed ID: 12884470
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.